TF and Familial prostate cancer: A hexavalent vaccine, prepared using GM2, Globo H, LeY, glycosylated MUC-1-32mer and Tn and TF antigens in a clustered formation, KLH conjugated and mixed with QS-21, was evaluated in 30 high-risk prostate cancer patients, inducing significantly high antibody titers in at least two of the six antigens [304].